Literature DB >> 24379641

DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach.

Takuya Wada1, Satoshi Tanabe1, Kenji Ishido1, Katsuhiko Higuchi1, Tohru Sasaki1, Chikatoshi Katada1, Mizutomo Azuma1, Akira Naruke1, Myunguchul Kim1, Wasaburo Koizumi1, Tetsuo Mikami1.   

Abstract

Approximately 80%-95% of gastrointestinal stromal tumors (GISTs) show positive staining for KIT, while the other 5%-20% show negative staining. If the tumor is negative for KIT, but is positive for CD34, a histological diagnosis is possible. However, if the tumor is negative for KIT, CD34, S-100, and SMA, a definitive diagnosis is often challenging. Recently, Discovered on GIST-1 (DOG1) has received considerable attention as a useful molecule for the diagnosis of GIST. DOG1, a membrane channel protein, is known to be overexpressed in GIST. Because the sensitivity and specificity of DOG1 are higher than those of KIT, positive staining for DOG1 has been reported, even in KIT-negative GISTs. KIT-negative GISTs most commonly arise in the stomach and are mainly characterized by epithelioid features histologically. We describe our experience with a rare case of a KIT-negative GIST of the stomach that was diagnosed by positive immunohistochemical staining for DOG1 in a patient who presented with severe anemia. Our findings suggest that immunohistochemical staining for DOG1, in addition to gene analysis, is useful for the diagnosis of KIT-negative tumors that are suspected to be GISTs.

Entities:  

Keywords:  Discovered on gastrointestinal stromal tumor-1; Gastrointestinal stromal tumors; KIT negative; Platelet-derived growth factor receptor alpha

Mesh:

Substances:

Year:  2013        PMID: 24379641      PMCID: PMC3870569          DOI: 10.3748/wjg.v19.i47.9133

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  A KIT-negative, DOG1-positive epithelioid GIST of the stomach harboring a novel PDGFRA exon 14 single nucleotide deletion.

Authors:  Clara Rizzardi; Stefania Marzinotto; Claudio Avellini; Mauro Melato; Laura Mariuzzi
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

2.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

3.  EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield.

Authors:  Paul S Sepe; Bhavani Moparty; Martha B Pitman; John R Saltzman; William R Brugge
Journal:  Gastrointest Endosc       Date:  2009-05-30       Impact factor: 9.427

Review 4.  Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

5.  EUS-guided sampling of suspected GI stromal tumors.

Authors:  Katherine M Hoda; Sarah A Rodriguez; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2009-04-25       Impact factor: 9.427

Review 6.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

7.  Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.

Authors:  Bernadette Liegl; Jason L Hornick; Christopher L Corless; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2009-03       Impact factor: 6.394

8.  A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.

Authors:  Inigo Espinosa; Cheng-Han Lee; Mi Kyung Kim; Bich-Tien Rouse; Subbaya Subramanian; Kelli Montgomery; Sushama Varma; Christopher L Corless; Michael C Heinrich; Kevin S Smith; Zhong Wang; Brian Rubin; Torsten O Nielsen; Robert S Seitz; Douglas T Ross; Robert B West; Michael L Cleary; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.

Authors:  Robert B West; Christopher L Corless; Xin Chen; Brian P Rubin; Subbaya Subramanian; Kelli Montgomery; Shirley Zhu; Catherine A Ball; Torsten O Nielsen; Rajiv Patel; John R Goldblum; Patrick O Brown; Michael C Heinrich; Matt van de Rijn
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more
  6 in total

1.  Perineurioma in the sigmoid colon diagnosed and treated by endoscopic resection.

Authors:  Yasuteru Fujino; Naoki Muguruma; Shinji Kitamura; Yasuhiro Mitsui; Tetsuo Kimura; Hiroshi Miyamoto; Hisanori Uehara; Koichi Kataoka; Tetsuji Takayama
Journal:  Clin J Gastroenterol       Date:  2014-08-19

2.  Lower Extremity Varicose Veins: An Unusual Presentation of Small Bowel Leiomyosarcoma.

Authors:  Karim Abou El Joud; Misha Abbasi
Journal:  Gastrointest Tumors       Date:  2021-11-18

3.  Synchronous Appearance of Adenocarcinoma and Gastrointestinal Stromal Tumour (GIST) of the Stomach: A Case Report.

Authors:  Ramesh Babu Telugu; Magesh Pushparaj; Dipti Masih; Anna Pulimood
Journal:  J Clin Diagn Res       Date:  2016-02-01

4.  Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.

Authors:  Francesca Maria Rizzo; Raffaele Palmirotta; Andrea Marzullo; Nicoletta Resta; Mauro Cives; Marco Tucci; Franco Silvestris
Journal:  BMC Cancer       Date:  2016-02-11       Impact factor: 4.430

Review 5.  Primary prostatic extragastrointestinal stromal tumor: a case report and literature review.

Authors:  Yong-Hao You; Yi Zhang
Journal:  J Int Med Res       Date:  2018-08-28       Impact factor: 1.671

Review 6.  Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.

Authors:  Xiao-Hui Qian; Ying-Cai Yan; Bing-Qiang Gao; Wei-Lin Wang
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.